Lebrikizumab Therapeutic Cheat Sheet
Lebrikizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively targets IL-13, a key cytokine implicated in the pathogenesis of type 2 inflammatory diseases.1 Lebrikizumab binds IL-13 with high affinity and a slow dissociation rate, which prevents heterodimerization of the IL-13 receptor alpha-1 subunit (IL-13Rα1) with the IL-4 receptor alpha (IL-4Rα) signaling complex. …
Lebrikizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively targets IL-13, a key cytokine implicated in the pathogenesis of type 2 inflammatory diseases.1 Lebrikizumab binds IL-13 with high affinity and a slow dissociation rate, which prevents heterodimerization of the IL-13 receptor alpha-1 subunit (IL-13Rα1) with the IL-4 receptor alpha (IL-4Rα) signaling complex. … 
Cabtreo is the first FDA-approved fixed-dose triple-combination topical treatment for acne vulgaris, pairing a lincosamide antibiotic (clindamycin), a synthetic retinoid (adapalene), and a keratolytic oxidizing agent (benzoyl peroxide) into a single once-daily gel. This formulation targets several pillars of acne pathogenesis simultaneously: cutaneous C. acnes proliferation, abnormal keratinizatio … 
Antihistamines, particularly second-generation histamine H1-receptor antagonists, are widely used in dermatology due to their antihistaminic activity and favorable safety profile characterized by minimal sedation compared with first-generation agents. They primarily act as peripheral H1-receptor antagonists, reducing histamine-mediated effects such as vasodilation, increased vascular permeability, … 
Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, is a cornerstone in the evolving field of immuno-oncology. Originally developed for advanced cancers, nivolumab functions by blocking PD-1–mediated immune suppression, thereby enhancing T-cell–mediated antitumor responses. In dermatology, its relevance has grown not only because of its utility in melanoma treatment and cutaneo … 
Photosensitive skin conditions can result in cutaneous and systemic symptoms that can have a marked effect on quality of life due to ubiquitous UV exposure. Erythropoietic protoporphyria, for example, can cause severe photodermatitis, excruciating burning and neuropathic pain, nausea, and deep-rooted fear of sunlight that leads to debilitating lifestyle modifications such as remaining indoors. We …